Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 5:53 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 8,135 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Period 1 Clear all

Conditions: Multiple Sclerosis, Exposure During Pregnancy
Interventions: Dimethyl fumarate, Peginterferon beta-1a; Drug
Lead sponsor: Biogen; Industry
Eligibility: Female only
Enrollment: 408 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Tic Disorder, Childhood, Comorbidities and Coexisting Conditions
Interventions: Combination of Comprehensive Behavioral Intervention for Tics (CBIT) and Evidence-based interventions for co-occurring diagnoses (i.e., Cognitive Behavioral Therapy, Behavioral Parent Training); Behavioral
Lead sponsor: Florida International University; Other
Eligibility: 7 Years to 17 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Dental Caries
Interventions: Test Dentifrice, Reference Dentifrice, Negative Control Dentifrice; Drug
Lead sponsor: HALEON; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Pediatric Obesity, Risk Reduction Behavior, Early Intervention, Intergenerational Relations
Interventions: Caregiver Component., Caregiver-Preschooler Learning., Center-based Preschooler Component.; Behavioral
Lead sponsor: Michigan State University; Other
Eligibility: 3 Years to 5 Years
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Lansing, Michigan

Conditions: Psoriatic Arthritis
Interventions: Placebo, Ixekizumab 80 mg Q4W, Ixekizumab 80 mg Q2W; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 363 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 59
States / cities: Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 50 more

Conditions: Other Cancer, Gastrointestinal Cancer, Thoracic Cancer, Gynecologic Cancer
Interventions: Stakeholder Survey (Control Period), Stakeholder Survey (Intervention Period), Qualitative Interview, SASS Questionnaire, eSyM; Other
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 42,808 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 6
States / cities: Portland, Maine • Boston, Massachusetts • Lebanon, New Hampshire + 3 more

Conditions: Healthy
Interventions: Opevesostat, Prednisone, Fludrocortisone acetate, Carbamazepine; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Diabetes Mellitus, Type 2, Diabetes Complications
Interventions: Diabetes Tune-Up Group; Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 21 Years and older · Female only
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Solid Tumors, Advanced Malignancies, Metastatic Cancer
Interventions: Azacitidine, Pembrolizumab, Epacadostat, INCB057643, INCB059872; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 8
States / cities: Duarte, California • La Jolla, California • Chicago, Illinois + 4 more

Conditions: Heart Failure With Preserved Ejection Fraction (HFpEF)
Interventions: AZD4831, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Glendale, California

Conditions: Cluster Headache, Episodic
Interventions: Eptinezumab, Placebo; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 24
States / cities: Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 19 more

Conditions: Graft-versus-Host Disease
Interventions: Bortezomib; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Myopia
Interventions: comfilcon A, lotrafilcon B; Device
Lead sponsor: CooperVision, Inc.; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 6
States / cities: Campbell, California • Whittier, California • Athens, Georgia + 3 more

Conditions: Healthy Volunteers
Interventions: ACP-196, Omeprazole; Drug
Lead sponsor: Acerta Pharma BV; Industry
Eligibility: 19 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Healthy Volunteers
Interventions: Period 1, Period 2; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Schizophrenia
Interventions: Risperidone, Olanzapine, Lu AF35700; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years and older
Enrollment: 1,098 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 49
States / cities: Bellflower, California • Cerritos, California • Costa Mesa, California + 39 more

Conditions: Metastatic Pancreatic Adenocarcinoma
Interventions: Tetrahydrouridine, Decitabine; Drug
Lead sponsor: Yogen Saunthararajah; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Cleveland, Ohio

Conditions: Non-alcoholic Steatohepatitis
Interventions: Placebo, Silymarin 700 mg, Silymarin 420 mg; Other · Drug
Lead sponsor: Madaus Inc; Industry
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 6
States / cities: Boston, Massachusetts • Chapel Hill, North Carolina • Philadelphia, Pennsylvania + 2 more

Conditions: Chronic Kidney Diseases
Interventions: Zibotentan, Dapagliflozin, Placebo, Dapagliflozin and Zibotentan; Drug
Lead sponsor: University Medical Center Groningen; Other
Eligibility: 18 Years to 75 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Glaucoma, Vision Disorder
Interventions: Virtual Reality Stimulation; Device
Lead sponsor: Stanford University; Other
Eligibility: 12 Years and older
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Language Delay, Language Development, Feeding; Difficult, Newborn, Mother-Infant Interaction, Maternal Behavior
Interventions: Oromotor stimulation, Reading curriculum, LENA recording, LENA linguistic feedback, No oromotor stimulation; Behavioral
Lead sponsor: Women and Infants Hospital of Rhode Island; Other
Eligibility: 23 Weeks to 30 Weeks
Enrollment: 124 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Spinal Cord Injuries
Interventions: Adaptive Rowing Exercise; Other
Lead sponsor: University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Columbia, South Carolina

Conditions: Amyotrophic Lateral Sclerosis (Healthy Volunteers)
Interventions: SAR443820; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Type 2 Diabetes
Interventions: Continuous Glucose Monitor and Undermyfork App, Continuous Glucose Monitor; Other
Lead sponsor: Scripps Whittier Diabetes Institute; Other
Eligibility: 18 Years to 80 Years
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: La Jolla, California

Search by objective public record fields.

Biogen Multiple Sclerosis Pregnancy Exposure Registry

Improving Symptom Trajectories of Tic Disorders and Co-occurring Diagnoses: The Role of Integrative Intensive Intervention

A Clinical Study to Assess an Experimental Dentifrice in an Experimental Model of Early Stage Caries

FirstStep2Health Intervention

A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis

Symptom Management Implementation of Patient Reported Outcomes in Oncology

A Drug-Drug Interaction Study of Carbamazepine and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-012)

Electronic Diabetes Tune-Up Group (eDTU) for African Americans

Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)

A Study to Assess the Effect AZD4831 in Japanese and Chinese Healthy Volunteers

Eptinezumab in Participants With Episodic Cluster Headache

Study on the Safety and Effectiveness of VELCADE® in the Treatment of Graft-Versus-Host Disease

A Multi-Center Study Comparing the Clinical Performance of Two Silicone Hydrogel Lenses Over 1 Month of Daily Wear

A Study to Evaluate the Effect of an Acidic Formulation of Acalabrutinib (ACP-196), Acidic Beverage, or Grapefruit Juice on the Pharmacokinetics (PK) of ACP-196 Alone and Coadministered With Omeprazole

Study To Investigate The Potential Drug Drug Interaction (DDI) Between PF-00299804 And Paroxetine In Healthy Subjects

Effect of Lu AF35700 in Patients With Treatment-resistant Schizophrenia

p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Pancreatic Cancer

Phase II Trial of Silymarin for Non-Cirrhotic Patients With Non-Alcoholic Steatohepatitis

Zibotentan and Dapagliflozin in Patients With Type 2 Diabetes and Elevated Albuminuria

Virtual Reality for Enhancement of Vision

Combined Oral Motor Stimulation and Language on Preterm Infant Feeding

Usability of the Adapted Rower for People With Spinal Cord Injury

A Study in Healthy Adult Male & Female Participants to Assess the Amount of the Study Medicine (SAR443820) Absorbed by the Body, When Given Orally in Fasted Condition as a Tablet Versus as a Capsule (Part 1) and When Given Orally as a Tablet in Fasted Condition Versus as a Tablet After Food (Part 2)

Pilot RCT Evaluating Clinical Outcomes of Using Undermyfork Mobile App With Dexcom G7